2014-09-03 21:32:53 UTC

Gastroenterology Podcast September 2014: Vedolizumab for Crohn’s Patients After TNF Therapy Has Failed

A study in the September issue of Gastroenterology evaluated the effects of vedolizumab induction therapy for patients with Crohn’s disease for whom tumor necrosis factor (TNF) antagonists have already failed. Dr. Kuemmerle speaks with the first author of the study, Dr. Bruce E. Sands of the Ichan School of Medicine at Mount Sinai, New York; Plus, a rundown of top stories from this month's issue of GI and Hepatology News.

 

 

Sands BE, Feagan BG, Rutgeerts P, et al. Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed. Gastroenterology 2014; September; 147(3): 618–627.e3
Abstract

 

 

Duration: 16.54m
Filetype: mp3
Bitrate: 96 KBPS
Frequency: 44100 HZ

More on Crohn's Disease

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Jan. 18, 2018

Expand your knowledge, network with IBD leaders, spark innovative research and get inspired to improve patient care.

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

Oct. 22, 2017

We investigated whether serum trough levels of vedolizumab, during the induction phase can determine whether patients need additional doses within 6 months.

Healing of Tonsillar Crohn’s Disease With Infliximab

Oct. 22, 2017